Cidara Therapeutics Inc (CDTX)
18.69
-1.71
(-8.38%)
USD |
NASDAQ |
Nov 25, 16:00
19.08
+0.39
(+2.09%)
After-Hours: 20:00
Cidara Therapeutics EPS Diluted (Quarterly): -2.45 for Sept. 30, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -2.45 |
| June 30, 2024 | -19.99 |
| March 31, 2024 | -2.28 |
| December 31, 2023 | -0.64 |
| September 30, 2023 | -2.02 |
| June 30, 2023 | -3.02 |
| March 31, 2023 | 0.60 |
| December 31, 2022 | -3.80 |
| September 30, 2022 | 3.40 |
| June 30, 2022 | -3.80 |
| March 31, 2022 | -5.40 |
| December 31, 2021 | -5.20 |
| September 30, 2021 | -7.40 |
| June 30, 2021 | 3.60 |
| March 31, 2021 | -7.80 |
| December 31, 2020 | -9.80 |
| September 30, 2020 | -8.20 |
| June 30, 2020 | -9.00 |
| March 31, 2020 | -9.20 |
| December 31, 2019 | -8.40 |
| September 30, 2019 | 1.60 |
| June 30, 2019 | -9.40 |
| Date | Value |
|---|---|
| March 31, 2019 | -11.60 |
| December 31, 2018 | -8.80 |
| September 30, 2018 | -9.80 |
| June 30, 2018 | -22.60 |
| March 31, 2018 | -16.00 |
| December 31, 2017 | -13.80 |
| September 30, 2017 | -14.60 |
| June 30, 2017 | -19.80 |
| March 31, 2017 | -16.00 |
| December 31, 2016 | -17.60 |
| September 30, 2016 | -17.60 |
| June 30, 2016 | -17.00 |
| March 31, 2016 | -14.20 |
| December 31, 2015 | -14.40 |
| September 30, 2015 | -13.40 |
| June 30, 2015 | -11.80 |
| March 31, 2015 | -10.61 |
| December 31, 2014 | -7.325 |
| September 30, 2014 | -21.66 |
| June 30, 2014 | -21.00 |
| March 31, 2014 | -4.613 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-19.99
Minimum
Jun 2024
3.60
Maximum
Jun 2021
-5.04
Average
-4.50
Median
EPS Diluted (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 0.55 |
| Arbutus Biopharma Corp | -0.10 |
| GlycoMimetics Inc | -0.15 |
| FibroGen Inc | -0.17 |
| Cue Biopharma Inc | -0.17 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -15.98M |
| Total Expenses (Quarterly) | 17.39M |
| Enterprise Value | 4.315M |
| Earnings Yield | -135.7% |
| Normalized Earnings Yield | -34.62 |